Liquidia Announces Oral Presentation at the 42nd Annual Meeting of International Society for Heart and Lung Transplant (ISHLT)
Liquidia Corporation (NASDAQ: LQDA) announced that Dr. Sandeep Sahay will present clinical data on YUTREPIA™ (treprostinil) inhalation powder at the 42nd Annual Meeting of the International Society for Heart and Lung Transplant in Boston. The presentation titled 'Risk Assessment in Pulmonary Arterial Hypertension (PAH): Insights from the INSPIRE Study' will occur on April 27, 2022. YUTREPIA, a treatment for PAH, received tentative FDA approval on November 5, 2021, aimed at improving exercise ability in adults with specific symptoms.
- YUTREPIA received tentative FDA approval on November 5, 2021.
- The presentation highlights data from the INSPIRE study, indicating ongoing research and development.
- None.
MORRISVILLE, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandeep Sahay, MD, from Houston Methodist Hospital will present clinical data from studies of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the 42nd Annual Meeting of International Society for Heart and Lung Transplant (ISHLT) in Boston, Massachusetts.
Presentation details of the oral, pre-recorded presentation are as follows:
| Title: | Risk Assessment in Pulmonary Arterial Hypertension (PAH): Insights from the INSPIRE Study with LIQ861 |
| Session: | SESS 19 (Oral) - Risky Business in Pulmonary Hypertension |
| Abstract Number: | 55 |
| Date/Time: | Wednesday, April 27; 3:30 p.m. – 3:40 p.m. ET |
| Location: | Ballroom A |
A copy of the presentation will be available on the company’s website at the time of the presentation.
About YUTREPIA™ (treprostinil) inhalation powder
YUTREPIA is an investigational, inhaled dry powder formulation of treprostinil delivered through a proven, convenient, palm-sized device. On November 5, 2021, the FDA issued a tentative approval for YUTREPIA, which is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape, and composition, and that are engineered for optimal deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso (nebulized treprostinil). YUTREPIA was previously referred to as LIQ861 in investigational studies.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.
Forward-Looking Statements
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Liquidia cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, the impact of the coronavirus (COVID-19) pandemic on our Company and our financial condition and results of operations; and other risks and uncertainties identified in the Company's filings with the U.S. Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Liquidia takes no obligation to update or revise these statements except as may be required by law.
Contact Information for Media & Investors
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
What is YUTREPIA and its significance for Liquidia (LQDA)?
When will the clinical data on YUTREPIA be presented?
Who is presenting the YUTREPIA data at the ISHLT meeting?
What was the purpose of the INSPIRE study in relation to YUTREPIA?
Where can I find the presentation on YUTREPIA after it is delivered?
